8-K: Beyond Air Secures $5M in Private Placement

Beyond Air, Inc. announced a $5.0 million private placement of common stock and warrants to an institutional investor, priced at-the-market under Nasdaq rules.

Summary

• Beyond Air, Inc. entered into a securities purchase agreement with an institutional investor on January 14, 2026, for a private placement offering.
• The company agreed to sell 524,990 shares of common stock at a purchase price of $1.272 per share.
• Pre-funded warrants to purchase up to 3,405,828 shares of common stock were sold at a purchase price of $1.2719 per pre-funded warrant, with an exercise price of $0.0001 per share.
• Common warrants to purchase up to 3,930,818 shares of common stock were also sold, with an exercise price of $1.147 per share and an expiration date of January 16, 2031.
• Each share and each pre-funded warrant was sold with an accompanying common warrant to purchase one share of common stock.
• The aggregate gross proceeds from the offering totaled $5,000,000.
• The offering closed on January 16, 2026, following the satisfaction of customary closing conditions.
• Rodman & Renshaw LLC acted as the exclusive placement agent, receiving a cash fee of 7.0% of the gross proceeds and reimbursement for up to $50,000 in out-of-pocket expenses.
• Roth Capital Partners and D. Boral Capital served as financial advisors to the company for the private placement.
• The company is required to file a resale registration statement by February 4, 2026, and aims for it to be declared effective within 60 days (or 90 days if subject to full SEC review).
• Restrictions are in place for 90 days after the registration statement's effective date, prohibiting the company from issuing certain common stock or common stock equivalents.
• For six months following the closing date, the company is also prohibited from effecting or entering into agreements for Variable Rate Transactions.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding for the company's ongoing operations and development, which is a positive for its continuity. However, the significant dilution from the issuance of new shares and warrants, along with associated fees, balances the overall sentiment to neutral-positive.

Positives

• Secured $5.0 million in gross proceeds, providing capital for working capital and general corporate purposes.
• The offering was priced 'at-the-market' under Nasdaq rules, indicating a market-aligned valuation for the transaction.
• Pre-funded warrants have a nominal exercise price of $0.0001 per share, making future conversion highly probable and providing a clear path to equity for investors.

Negatives

• The issuance of new shares and warrants will result in dilution for existing shareholders.
• Placement agent fees of 7.0% of gross proceeds and up to $50,000 in expenses reduce the net proceeds available to the company.
• The company is subject to restrictions on future equity issuances for specified periods, limiting its financial flexibility.

Risks

• Potential for dilution of existing shareholders' ownership percentage upon the exercise of the issued warrants.
• Risk of liquidated damages if the company fails to file or achieve effectiveness for the resale registration statement within the agreed-upon timelines.
• Market conditions and volatility could negatively impact the market price of the company's publicly-traded securities.
• Regulatory developments and approvals for the company's product candidates, including LungFit systems and Beyond Cancer, Ltd.'s investigations.
• Manufacturing, supply chain, and commercialization risks inherent in the medical device and biopharmaceutical industries.
• Changes in general economic, financial, regulatory, or political conditions could materially affect the company's business and prospects.

Future Outlook

The company intends to use the net proceeds from this private placement for working capital and general corporate purposes. It continues to advance its LungFit systems in clinical trials for severe lung infections and its affiliate, Beyond Cancer, Ltd., is investigating ultra-high concentrations of nitric oxide for solid tumors in pre-clinical settings.

Management Comments

• The company announced its entry into a securities purchase agreement with an institutional investor to issue and sell, in a private placement priced at-the-market under Nasdaq rules, 3,930,818 shares of common stock (or pre-funded warrants in lieu thereof), and warrants to purchase up to an aggregate of 3,930,818 shares of common stock, for expected gross proceeds of approximately $5.0 million.

Industry Context

This capital raise provides crucial funding for Beyond Air, a commercial-stage medical device and biopharmaceutical company operating in the specialized field of nitric oxide therapies. Such financing is typical for companies in this sector, which require substantial capital to fund ongoing clinical trials, research and development, and commercialization efforts. The 'at-the-market' pricing suggests the company is raising capital at prevailing market valuations, a common strategy for smaller-cap biotech firms to secure funds without significant discounts.

Comparison to Industry Standards

• The private placement structure, combining common stock, pre-funded warrants, and common warrants, is a standard financing mechanism utilized by small to mid-cap biopharmaceutical companies to raise capital, manage immediate dilution, and offer upside potential to investors.
• The 7.0% placement agent fee falls within the typical range for private placements of this size in the biotech sector, which generally varies between 5% and 10% depending on the deal's complexity and size.
• The beneficial ownership limitation (4.99% or 9.99%) is a common provision designed to prevent triggering certain beneficial ownership reporting requirements under SEC rules or anti-takeover provisions in corporate charters.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new shares and warrants, with potential for further dilution upon warrant exercise.
• Investors (Purchasers in this offering): Acquire equity and warrant positions, offering potential upside if the stock price increases, subject to beneficial ownership limitations.
• Company: Receives $5.0 million in gross proceeds to fund operations and development, but incurs costs for placement agent fees and offering expenses and is subject to restrictions on future equity issuances.

Next Steps

• File a resale registration statement with the SEC by February 4, 2026.
• Work to have the resale registration statement declared effective within 60 days (or 90 days if subject to full SEC review).
• Continue advancing LungFit systems in clinical trials for severe lung infections.
• Beyond Cancer, Ltd. will continue its pre-clinical investigation of ultra-high concentrations of nitric oxide for solid tumors.

Key Dates

Recommendation

The capital raise provides essential funding for Beyond Air's ongoing clinical development and general corporate purposes, which is a positive for the company's operational continuity. However, the significant dilution from the issuance of new shares and warrants, coupled with the associated fees, offsets some of this benefit. The 'at-the-market' pricing suggests the market is absorbing this offering without a deep discount, but the long-term value will depend on the successful execution of their clinical programs and commercialization efforts. For existing investors, holding is appropriate to monitor the utilization of these funds and progress on their pipeline. New investors might consider waiting for clearer milestones or a more favorable entry point given the recent dilution.

Keywords

Beyond Air, XAIR, private placement, common stock, pre-funded warrants, common warrants, capital raise, SEC filing, medical device, biopharmaceutical, nitric oxide, equity financing, institutional investor, dilution